Quintiles Ph I facility open at Guy’s Hospital ‘experimental medicine hub’

By Gareth Macdonald

- Last updated on GMT

Related tags: Genetics, Hospital

Contract research organisation (CRO) Quintiles gained new ‘first-in-human’ (FIH) trial capacity yesterday with the opening of an ‘experimental medicine hub’ at Guy’s Hospital in London, UK.

The new suite also houses a pharmacy for trial materials, labs for stem cell and genetic research and a study information centre and is designed to encourage patient participation and foster closer links between scientists and health professionals.

Quintiles, which collaborated​ on the project with Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, will operate the 30-bed Phase I unit for FIH and proof-of-concept drug research.

CEO Dennis Gillings, told attendees at the opening ceremony that: “The biopharma world is changing rapidly…it requires a new, highly collaborative approach that follows the “think global, act local” concept to ensure that scientific advances are translated into patient benefits.

Our involvement in the Experimental Medicine Hub has increased our capacity to conduct proof of concept programmes. These facilities bring Quintiles physically and professionally closer to academic and medical colleagues​.”

The opening of the Phase I centre follows just a few months after Quintiles partnered with another organisation in the English capital, genomics and proteomics specialist London Genetics (LG).

The accord, which was formed in November​, also focused on building the CRO’s presence in the rapidly developing experimental and personalised medical research sectors by leveraging LG’s capabilities in pharmacogenetics.

Phase I partnerships

The Guy’s Hospital Phase I unit is now one of six Quintiles operates and is the second to be opened this year behind the facility it unveiled in Hyderabad, India in January​.

Like the London site, Quintiles established the Hyderabad 86-bed, INR400m (€6m) centre through a collaboration, partnering with the Apollo Hospitals Group which retains a 40 per cent holding in the facility.

The opening in London follows just 24 hours​ after the US CRO confirmed that it is still continuing to assess various partnering, acquisition and investment opportunities to drive growth.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us


View more